Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
granulocyte-macrophage colony-stimulating factor + prostaglandin E1
- Development stage
- Preclinical
- Lead developer
- LMU Klinikum
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Granulocyte-macrophage colony-stimulating factor + prostaglandin E1 (also known as Kit-M) is an experimental immunomodulatory combination therapy being developed by Modiblast Pharma. It pairs granulocyte-macrophage colony-stimulating factor (GM-CSF), a recombinant cytokine, with prostaglandin E1 (PGE1, alprostadil), a small-molecule lipid mediator. The combination acts synergistically to convert myeloid leukemic blasts in whole blood or bone marrow into mature, antigen-presenting dendritic cells of leukemic origin (DC_leu). These DC_leu cells present leukemic antigens to the patient's own immune system, activating adaptive and innate immune cells (such as T cells, NK cells, and cytokine-induced killer cells) to target and lyse the remaining leukemic blasts without inducing blast proliferation. Kit-M is being developed for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with plans to enter Phase 1a/2b clinical trials.
- Other names
- GM-CSF + alprostadilGM-CSF + PGE-1GM-CSF + PGE1GM-CSF + prostaglandin E1granulocyte-macrophage colony-stimulating factor + alprostadilmolgramostim + alprostadilmolgramostim + prostaglandin E1sargramostim + alprostadilsargramostim + prostaglandin E1
02
Targets
CSF2RB (Cytokine receptor common subunit beta)CSF2RA (Granulocyte-macrophage colony-stimulating factor receptor subunit alpha)PTGIR (Prostanoid IP Receptor)PTGER1 (Prostaglandin E Receptor 1)PTGER2 (Prostaglandin E2 receptor EP2)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on granulocyte-macrophage colony-stimulating factor + prostaglandin E1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on granulocyte-macrophage colony-stimulating factor + prostaglandin E1.